{"url_path":"/sec/immx/8-k/2026-05-21/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1873835/0001493152-26-024707-index.html","accession_number":"0001493152-26-024707","cik":"0001873835","ticker":"IMMX","issuer_name":"Immix Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1873835/0001493152-26-024707-index.html","primary_entity_key":"0001873835","primary_entity_name":"Immix Biopharma, Inc."},"word_count":203,"has_tables":true,"body_markdown":"** **\n\n**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nMay 21, 2026, Immix Biopharma, Inc. (the “Company”) issued a press release announcing that all four MRD-negative relapsed/refractory\nlight chain (“AL”) Amyloidosis patients announced by the Company at the American Society of Hematology 2025 Annual Meeting\n(“ASH 2025”) held in Orlando, Florida in December have converted to complete response (“CR”). A copy of the press\nrelease is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”).\n\n \n\nIn\naccordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report and Exhibit 99.1 attached hereto\nshall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange\nAct”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration\nstatement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set\nforth by specific reference in such filing. In addition, the information set forth under this Item 7.01, including Exhibit 99.1, shall\nnot be deemed an admission as to the materiality of any information in this Current Report."}